Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes
暂无分享,去创建一个
I. Sandovici | F. Pezzella | A. Hassan | D. Barnes | M. Constância | C. Graham | E. Carter | V. Haley | C. Bühnemann | D. J. Barnes | A. B. Hassan | Christopher F. Graham | Victoria L. Haley | David J. Barnes | Emma J. Carter
[1] W. Blattner,et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.
[2] C. Prives,et al. Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.
[3] R. Jaenisch,et al. DNA hypomethylation can activate Xist expression and silence X-linked genes. , 1996, Genes & development.
[4] Mary F. Lopez,et al. Igf2 deficiency results in delayed lung development at the end of gestation. , 2006, Endocrinology.
[5] James D. Brenton,et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer , 2008, Human molecular genetics.
[6] Douglas Hanahan,et al. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010, Proceedings of the National Academy of Sciences.
[7] C. Purdie,et al. Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.
[8] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[9] L. Donehower. Does p53 affect organismal aging? , 2002, Journal of cellular physiology.
[10] S. Baker,et al. PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.
[11] M. Mclaughlin,et al. Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression , 2011, Cell.
[12] A. Hassan,et al. Insulin-like Growth Factor II Supply Modifies Growth of Intestinal Adenoma in ApcMin/+ Mice , 2000 .
[13] Melinda Larsen,et al. Fibronectin requirement in branching morphogenesis , 2003, Nature.
[14] R. Jaenisch,et al. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. , 2007, Genes & development.
[15] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[16] A. Levine,et al. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. , 2010, Trends in cell biology.
[17] Masahiro Sato,et al. The expression profile of microRNAs in mouse embryos , 2006, Nucleic acids research.
[18] M. Kaufman,et al. High-frequency developmental abnormalities in p53-deficient mice , 1995, Current Biology.
[19] L. Mayo,et al. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[20] A. Gabory,et al. The H19 locus acts in vivo as a tumor suppressor , 2008, Proceedings of the National Academy of Sciences.
[21] L. Donehower,et al. Genetic background alters the spectrum of tumors that develop in p53‐deficient mice , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[22] Laurent Journot,et al. H19 acts as a trans regulator of the imprinted gene network controlling growth in mice , 2009, Development.
[23] A. Levine,et al. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. , 2007, Cancer research.
[24] Zhihui Feng,et al. DNA Damage Induces p53-dependent BRCA1 Nuclear Export* , 2004, Journal of Biological Chemistry.
[25] S. Tilghman,et al. Disruption of imprinting caused by deletion of the H19 gene region in mice , 1995, Nature.
[26] T. Jacks,et al. Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.
[27] A. Hassan,et al. Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. , 2000, Cancer research.
[28] D. Hanahan,et al. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis , 1994, Nature.
[29] Graziano Pesole,et al. Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes , 2009, Nucleic Acids Res..
[30] R. Weinberg,et al. Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.
[31] S. Velasco-Miguel,et al. Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.
[32] J. Harper,et al. Insulin‐like growth factor ligands, receptors, and binding proteins in cancer , 2005, The Journal of pathology.
[33] R. Jaenisch,et al. Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.
[34] E. Jones,et al. Kinetics of insulin-like growth factor II (IGF-II) interaction with domain 11 of the human IGF-II/mannose 6-phosphate receptor: function of CD and AB loop solvent-exposed residues. , 2006, Journal of molecular biology.
[35] Eduardo Sontag,et al. Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.
[36] Arnold J Levine,et al. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. , 2010, Cancer cell.
[37] A. Hassan,et al. Cell survival and proliferation are modified by insulin-like growth factor 2 between days 9 and 10 of mouse gestation. , 2001, Development.
[38] A. Efstratiadis,et al. Parental imprinting of the mouse insulin-like growth factor II gene , 1991, Cell.
[39] T. Mak,et al. Regulation of PTEN transcription by p53. , 2001, Molecular cell.
[40] J. Beyene,et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.
[41] A. El‐Naggar,et al. Multiple stress signals activate mutant p53 in vivo. , 2011, Cancer research.
[42] F. Kashanchi,et al. Regulation of insulin-like growth factor II P3 promotor by p53: a potential mechanism for tumorigenesis. , 1996, Cancer research.
[43] Michael Karin,et al. p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling , 2009, Cell.
[44] C. McKerlie,et al. Respiratory Distress and Neonatal Lethality in Mice Lacking Golgi α1,2-Mannosidase IB Involved in N-Glycan Maturation* , 2007, Journal of Biological Chemistry.
[45] J. Marine,et al. Mdm2-mediated ubiquitylation: p53 and beyond , 2010, Cell Death and Differentiation.
[46] Hiroyuki Yamamoto,et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. , 2010, Carcinogenesis.
[47] Carlos Cordon-Cardo,et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.
[48] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[49] H. Scrable,et al. Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. , 2010, Genes & development.
[50] Sook Y. Lee,et al. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma , 2000, Oncogene.
[51] Charmaine D. Wilson,et al. Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations , 2010, PloS one.
[52] L. Donehower,et al. Timed Somatic Deletion of p53 in Mice Reveals Age-Associated Differences in Tumor Progression , 2009, PloS one.
[53] Elizabeth J. Robertson,et al. Role of insulin-like growth factors in embryonic and postnatal growth , 1993, Cell.
[54] S. Shete,et al. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. , 2006, Cancer research.
[55] Li-fraumeni syndrome. , 2007, Genes & cancer.
[56] D. Page,et al. Zfx mutation results in small animal size and reduced germ cell number in male and female mice. , 1997, Development.
[57] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[58] B. Cullen,et al. The imprinted H19 noncoding RNA is a primary microRNA precursor. , 2007, RNA.
[59] R. Kuick,et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.
[60] Alberto Inga,et al. The expanding universe of p53 targets , 2009, Nature Reviews Cancer.
[61] A. Yang,et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. , 2002, Molecular cell.
[62] L. Donehower. Longevity regulation in flies: A role for p53 , 2009, Aging.
[63] B. Sohn,et al. Deregulation of DNA methyltransferases and loss of parental methylation at the insulin‐like growth factor II (Igf2)/H19 loci in p53 knockout mice prior to tumor development , 2005, Journal of cellular biochemistry.
[64] Pan Du,et al. lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..
[65] Gerard I. Evan,et al. Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.
[66] F. Kashanchi,et al. p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. , 1998, DNA and Cell Biology.
[67] G. Sauvageau,et al. Zfx: At the Crossroads of Survival and Self-Renewal , 2007, Cell.
[68] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[69] S. Avnet,et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. , 2009, Cancer research.
[70] B. Alman,et al. Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. , 2009, Cancer cell.
[71] A. Harris,et al. Igf2 ligand dependency of Pten+/− developmental and tumour phenotypes in the mouse , 2011, Oncogene.
[72] C. Croce,et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. , 2010, Cancer research.
[73] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[74] S. Kornfeld,et al. Mannose 6-phosphate receptors: new twists in the tale , 2003, Nature Reviews Molecular Cell Biology.
[75] A. Efstratiadis,et al. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting , 1990, Nature.
[76] Shirley M. Taylor,et al. p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. , 2003, Cancer research.
[77] D. Hanahan,et al. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. , 2002, Cancer cell.
[78] H. Werner,et al. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[79] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[80] D. Hanahan,et al. Deregulation of both imprinted and expressed alleles of the insulin–like growth factor 2 gene during β–cell tumorigenesis , 1995, Nature Genetics.